|
| 异麦芽糖酐铁治疗105例肿瘤相关性贫血的临床研究 |
| Clinical Study of Iron Isomaltoside in the Treatment of 105 Cases of Cancer-Related Anemia |
| 投稿时间：2026-07-20 修订日期：2026-09-18 |
| DOI： |
|
 |
| 中文关键词: 异麦芽糖酐铁 恶性肿瘤 肿瘤相关性贫血 |
| 英文关键词:Iron isomaltoside Anemia Cancer related anemia |
| 基金项目:1.北京市垂杨柳医院科技发展基金栋梁项目（项目编号：YN202402 伦理号2024-031KY）；2.北京市垂杨柳医院科技发展基金（项目编号：YN202410 伦理号2024-033KY） |
|
| 摘要点击次数: 7 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：评估静脉注射异麦芽糖酐铁治疗肿瘤相关性贫血（cancer-related anemia, CRA）伴缺铁患者的疗效与安全性，并与口服琥珀酸亚铁进行对比。方法：分析2024年7月1日至2026年6月30日期间我院收治的105例CRA伴缺铁患者，将其分为静脉输注异麦芽糖酐铁组（试验组，62例）和口服琥珀酸亚铁片组（对照组，43例）。观察并比较两组患者治疗后4周、8周的血红蛋白（hemoglobin, Hb）应答率、血红蛋白水平、铁代谢指标变化、药物安全性等，并进行多因素分析以探讨影响疗效的因素。结果：异麦芽糖酐铁组治疗后4周、8周的Hb应答率分别为54.8%和83.1%。治疗后8周，静脉铁剂组的Hb应答率（83.1%）显著高于口服铁剂组（54.5%）。静脉铁剂在治疗4周时即可显著提升Hb水平并改善铁储备（如转铁蛋白饱和度），起效快于口服铁剂。安全性方面，静脉铁剂组仅发生1例轻微不良反应，总体耐受性良好。多因素分析显示，女性是获得早期（4周）Hb应答的独立有利预测因素。亚组分析表明，异麦芽糖酐铁的疗效优势在不同肿瘤类型中具有一致性。结论：静脉注射异麦芽糖酐铁是治疗CRA伴缺铁的有效、安全的方法。相较于口服铁剂，它能更快速、显著地纠正贫血和缺铁状态。女性患者可能获得更优的短期疗效。 |
| 英文摘要: |
| Objective:To evaluate the efficacy and safety of intravenous iron isomaltoside in the treatment of cancer-related anemia (CRA) complicated with iron deficiency, and to compare it with oral ferrous succinate.Methods:A total of 105 patients with CRA complicated with iron deficiency admitted to our hospital from July 1, 2024 to June 30, 2026 were analyzed and divided into an intravenous iron isomaltoside group (experimental group, 62 cases) and an oral ferrous succinate tablet group (control group, 43 cases). The hemoglobin (Hb) response rate, Hb level, changes in iron metabolism indicators, and drug safety were observed and compared between the two groups at 4 and 8 weeks after treatment. Multivariate analysis was performed to explore the factors influencing therapeutic efficacy.Results: The Hb response rates at 4 and 8 weeks after treatment in the intravenous iron isomaltoside group were 54.8% and 83.1%, respectively. At 8 weeks after treatment, the Hb response rate in the intravenous iron group (83.1%) was significantly higher than that in the oral iron group (54.5%). Intravenous iron significantly increased Hb levels and improved iron stores (e.g., transferrin saturation) as early as 4 weeks of treatment, with a faster onset of action than oral iron. In terms of safety, only one mild adverse reaction occurred in the intravenous iron group, and the overall tolerability was good. Multivariate analysis showed that female sex was an independent favorable predictor of early (4-week) Hb response. Subgroup analysis indicated that the therapeutic advantage of iron isomaltoside was consistent across different tumor types.Conclusion: Intravenous iron isomaltoside is an effective and safe treatment for CRA complicated with iron deficiency. Compared with oral iron, it corrects anemia and iron deficiency more rapidly and significantly. Female patients may achieve better short-term therapeutic efficacy. |
|
在线阅读
查看/发表评论 下载PDF阅读器 |
|
|
|